Biotech News News 9 October 2025

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Sources: Official press releases and filings investors.adverum.com investors.adverum.com, Reuters, Investing.com, Fierce Biotech fiercebiotech.com, and analyst reports marketbeat.com marketbeat.com. All data as of market close Oct. 23, 2025 and news through Oct. 24,

24 October 2025

Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish

Stock Performance and Recent Rally Ventyx Biosciences has been one of 2025’s biggest small-cap biotech movers. The Nasdaq-listed stock jumped sharply on Oct. 22 after hours, when the company announced the positive

23 October 2025

Biotech News · Financial Trends · Health Innovations · Investment Analysis · NASDAQ:VTYX · Stock Market

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year

22 October 2025

Biotech News · Financial Analysis · Investment Tips · NASDAQ:ARCT · Pharma Industry · Stock Market

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Stock Performance and Recent Rally Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that

21 October 2025

Biotech News · FDA Approvals · Financial Markets · Investment Analysis · NASDAQ:REPL · Stock Market

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration

18 October 2025

Biotech News · Company Collaborations · Investment Analysis · NASDAQ:RANI · Pharmaceuticals · Stock Market

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Key Facts – October 18, 2025 RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and

18 October 2025

Biotech News · Investing · Mergers & Acquisitions · NASDAQ:RANI · Pharmaceutical Industry · Stock Market

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments

17 October 2025

Biotech News · FDA Approvals · Financial Analysis · Investment Strategies · NASDAQ:ARTV · Stock Market

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Record Stock Surge on Phase 3 Breakthrough Praxis Precision Medicines shares skyrocketed on October 16, 2025, after the biotech reported game-changing Phase 3 trial results for its essential tremor drug. The stock closed

17 October 2025

Biotech News · Clinical Trials · Financial Trends · Investment Analysis · Stock Market

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the

16 October 2025

Biotech News · FDA Approvals · Investment Insights · Pharmaceuticals · Stock Market

Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-October stockinvest.us, but the new AI partnership sent them soaring in

16 October 2025

AI Technology · Biotech News · Financial Analysis · Investing · Stock Market

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded

16 October 2025

Biotech News · Cancer Research · Investment Insights · Pharma Updates · Stock Market

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.

9 October 2025

Biotech News · Investment Insights · Mergers & Acquisitions · NASDAQ:AKRO · NYSE:NVO · Pharma Industry · Stock Market

Biotech News News 9 October 2025 - 24 October 2025